211 related articles for article (PubMed ID: 25924010)
1. Resolution of Benign and Malignant Sebaceous Neoplasms, in a Renal Transplant Patient Treated With Everolimus.
Donati M; Paolino G; Muscardin L; Panetta C; Donati P
Exp Clin Transplant; 2017 Feb; 15(1):100-102. PubMed ID: 25924010
[TBL] [Abstract][Full Text] [Related]
2. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome.
Levi Z; Hazazi R; Kedar-Barnes I; Hodak E; Gal E; Mor E; Niv Y; Winkler J
Am J Transplant; 2007 Feb; 7(2):476-9. PubMed ID: 17229076
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
4. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.
Harwood CA; Swale VJ; Bataille VA; Quinn AG; Ghali L; Patel SV; Dove-Edwin I; Cerio R; McGregor JM
J Invest Dermatol; 2001 Feb; 116(2):246-53. PubMed ID: 11180000
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
6. Eruptive sebaceous hyperplasia as a side effect of oral tacrolimus in a renal transplant recipient.
Levandoski KA; Girardi NA; Loss MJ
Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537866
[TBL] [Abstract][Full Text] [Related]
7. Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature.
Velioglu A; Eryuksel E; Cimsit C; Tuglular S; Ozener C
Exp Clin Transplant; 2018 Aug; 16(4):491-494. PubMed ID: 27001620
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of basal cell carcinomas and multiple sebaceous gland hyperplasias in a cyclosporine (ciclosporin)-treated renal transplant recipient.
Yayli S; Akyazi H; Bahadir S; Alpay K; Cobanoğlu U
Am J Clin Dermatol; 2010; 11(1):59-62. PubMed ID: 20000877
[TBL] [Abstract][Full Text] [Related]
9. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
[TBL] [Abstract][Full Text] [Related]
10. An Atypical Presentation of Thrombotic Microangiopathy After Lung Transplant: A Case Report.
Menezes MDM; Aires I; Semedo L; Calado J; Ribeiro F; Nolasco F
Transplant Proc; 2019 Jun; 51(5):1633-1635. PubMed ID: 31155208
[TBL] [Abstract][Full Text] [Related]
11. Borderline sebaceous neoplasm in a renal transplant patient without Muir-Torre syndrome.
Kaminska EC; Iyengar V; Tsoukas M; Shea CR
J Cutan Pathol; 2013 Mar; 40(3):336-40. PubMed ID: 23174034
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Sebaceous Lesions in a Patient With MUTYH-Associated Polyposis Mimicking Muir-Torre Syndrome.
Kacerovska D; Drlik L; Slezakova L; Michal M; Stehlik J; Sedivcova M; Hadravsky L; Kazakov DV
Am J Dermatopathol; 2016 Dec; 38(12):915-923. PubMed ID: 27870730
[TBL] [Abstract][Full Text] [Related]
13. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
14. Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report.
Detroyer D; Deraedt K; Schöffski P; Hauben E; Lagrou K; Naesens M; Delforge ML; Kuypers D
Transpl Infect Dis; 2015 Apr; 17(2):303-7. PubMed ID: 25645490
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
16. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
17. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
[TBL] [Abstract][Full Text] [Related]
18. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
19. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
20. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
